Figure 6
Measurement of α1 Na/K-ATPase expression in primary tumor and metastatic lesions- (a) The expression of α1 Na/K-ATPase in prostate cancer. Left panels show α1 expression patterns in paired human normal prostate tissue (left), carcinoma (middle) and bone metastasis (right). Human tissue arrays were immunostained with a α1 monoclonal antibody (in brown). Hematoxylin was used for counterstaining of cell nucleus (in blue). Quantitative data are shown on the right side. **p < 0.0001 (one-way ANOVA, Bartlett’s test). Down-regulation of α1 Na/K-ATPase in prostate cancer was further verified by paired tissue analysis (right-most panel) **p < 0.001, paired T-test (Wilcoxon signed-rank test). (b,c) The expression of α1 Na/K-ATPase in breast and kidney cancers. Left panels show α1 Na/K-ATPase expression patterns in normal tissues, cancer and metastatic lesions as in A. Right panel shows quantitative data of α1 staining. **p < 0.0001 (one-way ANOVA, Bartlett’s test). (d) Comparison of α1 Na/K-ATPase expression in three different human cancers. Quantitative measurements of Na/K-ATPase α1 expression in Panel a-c are tabled. (e) Transcriptional down-regulation of Na/K-ATPase α1 (ATP1A1) gene expression and kidney cancer patient survival. The left panel shows a decrease in α1 expression in human kidney cancer (TCGA-KIRC database, n = 530), paired T-test (Wilcoxon signed-rank test). The right panel shows an inverse correlation between the α1 gene expression and patient survival (log-rank survival test).
